InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Fuhrman Alan, Director. Director active across 4 companies, notably SpringWorks Therapeutics, Inc.. In total, 16 disclosures have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €140k. History available since 20 May 2021. The latest transaction was filed on 13 March 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Fuhrman Alan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
1,376 shares@ US$9.1295.4% of flowCommon StockSEC:0001193125-26-111100:0
701 shares@ US$9.1292.6% of flowCommon StockSEC:0001193125-25-206439:0
24,727 sharesCommon StockSEC:0001104659-25-065312:0
10,060 shares0Common StockSEC:0001104659-25-049658:0
1,238 shares@ US$9.7755.9% of flowCommon StockSEC:0000950170-25-041550:0
9,500 shares@ US$15.995273.8% of flowCommon StockSEC:0000950170-24-120099:0
Canonical exit: 28 Jan 2025 (T+90)
954 shares@ US$12.4785.6% of flowCommon StockSEC:0000950170-24-107391:0
23,000 shares0Common StockSEC:0001628280-24-025219:0
4,095 shares0Common StockSEC:0001104659-24-062978:0
932 shares@ US$12.4785.6% of flowCommon StockSEC:0000950170-24-033848:0
1,463 shares@ US$12.5035100.0% of flowCommon StockSEC:0001209191-23-050090:0
5,150 shares0Common StockSEC:0001628280-23-022461:0
4,648 shares0Common StockSEC:0001104659-23-064645:0
4,818 shares0Common StockSEC:0001104659-22-063507:0
12,376 shares0Common StockSEC:0001628280-21-011361:0
1,106 shares0Common StockSEC:0001104659-21-070519:0
16 of 16 declarations
About Fuhrman Alan
Fuhrman Alan is Administrateur and has filed 16 disclosures in total. Across the 16 most recent sampled disclosures, buy amounts total EUR 140430, sell amounts total EUR 0, and the most frequent transaction nature is Attribution, with disclosures ranging from 2021-05-21 to 2026-03-17. He is also Chief Financial Officer at Tyra Biosciences, Inc., and Director at SpringWorks Therapeutics, Inc. and Esperion Therapeutics, Inc.
